Linda Stocum, Associate Editor

ICYMI, this week we had stories on the newest FDA approvals, biologic therapy in plaque psoriasis, and more.

The results from the American Academy of Facial Plastic and Reconstructive Surgery annual survey showed an uptick in demand for facial plastic surgery, an increase in popularity for lifts and lasers, and a growing gender neutrality in patients.

The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.

The American Society for Dermatologic Surgery investigated how the COVID-19 pandemic affected both dermatology practices and patients from staffing reductions to telehealth.

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Tralokinumab-ldrm (Adbry; LEO Pharma) showed improvement in itch, sleep, anxiety, depression, and overall quality of life data for adolescent AD patients in newly released study data.

Allergan Aesthetics, an AbbVie company, announced the FDA approval of Juvéderm Volbella XC for undereye hollows.

This week's edition of the Mainstream Patients features stories about the benefits of castor oil, the controversy of fragranced skin care, and more.

ICYMI, this week we had stories on skin lightening controversies, what's trending in skin care, and more.

Trevi Therapeutics has completed enrollment for its phase 2b/3 PRISM study in chronic pruritus in prurigo nodularis.

This episode of The Cutaneous Connection podcast dives into androgenetic alopecia or AGA is a common form of hair loss in both men and women. Maryanne Makredes Senna, MD, assistant professor of dermatology at Harvard Medical school, and director of the Mass General Hospital Hair Loss Clinic and clinical research trials for hair loss disorders in Boston, Massachusetts, highlights current treatment challenges, new regeneration devices, and how to help patients with texture hair.

A dermatologist needs to know how to treat every patient, regardless of skin or hair type. These pointers will help guide conversations with patients for the best possible hair care.

Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of January.

ICYMI, this week we had stories on hormonal acne, skin cancer testing, and more.

AbbVie announced the FDA approval to their IL-23 inhibitor risankizumab-rzaa (Skyrizi) for treatment of active psoriatic arthritis (PsA) in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.

Poster presented at Maui Derm for Dermatologists 2022 reveals prognostic value of 2 independently validated algorithms.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.

A poster presentation from Follica at the 2022 Winter Clinical Dermatology Conference and 2022 Maui Derm for Dermatology meeting found that 56% of survey responders did not seek treatment for their hair loss, and that 19% of respondents who attempted treatment quit because of lack of efficacy or cost.

ICYMI, this week we had stories on infectious diseases, new drug approvals, and more.

Will Kirby, DO, FAOCD, board-certified dermatologist, chief medical officer of LaserAway, and Dermatology Times® editorial board member, will be speaking at the Medical Spa Show, presented by the American Med Spa Association.

A research letter published by the Journal of the American Academy of Dermatology dove into the question of how psoriasis may increase the overall risk of cutaneous malignant melanoma in patients.

A study published in the Journal of the American Academy of Dermatology did a prospective analysis on psoriasis biologic treatment response related to comorbid obesity and a history of diabetes.

Dermavant had patient satisfaction data from the PSOARING 3 long term extension trial presented at the 2022 Winter Clinical Dermatology Conference.

Vial announced an advisory board to discuss dermatology CROs at the 2022 Winter Clinical Dermatology Conference.

The FDA has approved abrocitinib for adult patients with moderate to severe AD.

Resident billing can have huge financial implications on academic institutions. A poster from the Icahn School of Medicine at Mount Sinai aimed to assess new medical coding lectures and a modified note template at Winter Clinical Dermatology Conference.

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Ted Rosen, MD, explains the top points of his presentation, "What's Hot and New in Infectious Disease?" from the 2022 Winter Clinical Dermatology Conference.

In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).